UK Pharmacy

On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.

IMPORTANT NOTICE

December 2024: We face an immediate shortage of our current baloxavir supply and so we have had to change supply arrangements, which have just received approval as SA36. Please note:

• Oseltamivir will now be supplied from NHS stock (like dexamethasone), and there will be no trial-specific oseltamivir supply. This has been reflected in the updated SoECAT, and we hope this will make the comparison simpler for sites.
• The new baloxavir supply will be labelled like a typical clinical trial IMP and will be provided in packs of 2 x 20mg tablets rather than 1x40mg tablet. However, there is no difference in how baloxavir is used in the trial, and SA36 does not alter the protocol, trial procedures, consent forms, or reference safety information.
• Documents and approvals for SA36 are on the regulatory documents page
• Ordering baloxavir will now involve emailing the Oxford trial team directly, who will dispatch orders via the Roche clinical trial distribution system. Instructions for ordering, including a template email, are in the updated pharmacy manual below.

We will activate the new ordering system the week commencing 16th December, and deliver an initial shipment of the new baloxavir supply to all sites without the need for a request. Any existing baloxavir or oseltamivir at sites can still be used for trial patients, but orders via the old supply system will no longer be processed.